Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1245/s10434-024-16048-4 | DOI Listing |
Ann Surg Oncol
December 2024
Gastric and Mixed Tumor Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Circulation
January 2025
Division of Cardiology, Department of Medicine, Emory Clinical Cardiovascular Research Institute; and Emory University School of Medicine, Atlanta, GA (L.S.S.).
There is a new awareness of the widespread nature of metabolic dysfunction-associated steatotic liver disease (MASLD) and its connection to cardiovascular disease (CVD). This has catalyzed collaboration between cardiologists, hepatologists, endocrinologists, and the wider multidisciplinary team to address the need for earlier identification of those with MASLD who are at increased risk for CVD. The overlap in the pathophysiologic processes and parallel prevalence of CVD, metabolic syndrome, and MASLD highlight the multisystem consequences of poor cardiovascular-liver-metabolic health.
View Article and Find Full Text PDFAnn Surg Oncol
December 2024
Division of Digestive Surgery IEO, European Institute of Oncology IRCCS, Milan, Italy.
Ann Surg Oncol
December 2024
Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montreal, QC, Canada.
Ann Surg Oncol
December 2024
Hepato-Pancreato-Biliary Surgery and Liver Transplantation, Pôle des Pathologies Hépatiques et Digestives, Hôpital de Hautepierre-Hôpitaux Universitaires de Strasbourg, Université de Strasbourg, Strasbourg, France.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!